

# Quest Diagnostics Drug Testing Index™

Full year 2023 tables

**Table 1. Annual Positivity Rates – Urine Drug Tests  
(For Combined U.S. Workforce)**



*(More than 8.4 million tests from January to December 2023)*

<b>Year</b>	<b>Drug Positivity Rate</b>
1988	13.6%
1989	12.7%
1990	11.0%
1991	8.8%
1992	8.8%
1993	8.4%
1994	7.5%
1995	6.7%
1996	5.8%
1997	5.0%
1998	4.8%
1999	4.6%
2000	4.7%
2001	4.6%
2002	4.4%
2003	4.5%
2004	4.4%
2005	4.0%
2006	3.8%
2007	3.8%
2008	3.6%
2009	3.6%
2010	3.5%
2011	3.5%
2012	3.5%
2013	3.7%
2014	3.9%
2015	4.0%
2016	4.2%
2017	4.2%
2018	4.4%
2019	4.5%
2020	4.4%
2021	4.6%
2022	4.6%
2023	4.6%

**Table 2. Positivity Rates by Testing Category – Urine Drug Tests**

Testing Category	2019	2020	2021	2022	2023
Federally Mandated, Safety-Sensitive Workforce	2.4%	2.2%	2.2%	2.4%	2.4%
General U.S. Workforce	5.3%	5.5%	5.6%	5.7%	5.7%
Combined U.S. Workforce	4.5%	4.4%	4.6%	4.6%	4.6%

**Table 3. Positivity Rates by Testing Reason – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce)***(More than 2.8 million tests from January to December 2023)*

Testing Reason	2019	2020	2021	2022	2023
Follow-Up	5.1%	4.6%	4.3%	4.2%	3.8%
For Cause	13.0%	12.7%	13.8%	12.9%	14.5%
Post-Accident	4.5%	4.3%	4.4%	4.5%	4.6%
Pre-Employment	2.4%	2.1%	2.3%	2.5%	2.5%
Random	2.2%	2.0%	1.9%	1.9%	2.0%
Return to Duty	5.0%	4.5%	4.7%	4.9%	5.2%

**Table 4. Positivity Rates by Testing Reason – Urine Drug Tests (For General U.S. Workforce)***(More than 5.5 million tests from January to December 2023)*

Testing Reason	2019	2020	2021	2022	2023
Follow-Up	8.3%	7.1%	7.1%	7.3%	8.8%
For Cause	35.7%	34.7%	34.9%	38.6%	39.4%
Post-Accident	9.1%	9.5%	9.7%	10.3%	10.4%
Pre-Employment	4.9%	5.2%	5.4%	5.5%	5.4%
Random	5.6%	5.8%	5.8%	5.9%	6.0%
Return to Duty	6.8%	6.2%	6.3%	7.0%	8.4%

**Table 5. Positivity Rates by Drug Category – Urine Drug Tests  
(For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)**

*(More than 2.8 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM	0.011%	0.008%	0.005%	0.003%	0.003%
Amphetamines (Amphetamine/Methamphetamine)	0.68%	0.64%	0.69%	0.75%	0.76%
Cocaine	0.25%	0.20%	0.21%	0.21%	0.21%
Marijuana	0.88%	0.79%	0.86%	0.98%	0.95%
MDMA (MDMA/MDA)	0.003%	0.002%	0.002%	0.003%	0.003%
Opiates (Codeine/Morphine)	0.12%	0.10%	0.08%	0.08%	0.07%
Opiates (Hydrocodone/Hydromorphone)	0.35%	0.30%	0.27%	0.24%	0.22%
Oxycodones (Oxycodone/Oxymorphone)	0.26%	0.21%	0.20%	0.18%	0.18%
PCP	0.011%	0.011%	0.010%	0.009%	0.008%

**Table 6. Positivity Rates by Drug Category – Urine Drug Tests  
(For General U.S. Workforce, as a percentage of all such tests)**

*(More than 5.5 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM	0.02%	0.018%	0.013%	0.006%	0.005%
Amphetamines (Amphetamine/Methamphetamine)	1.3%	1.3%	1.3%	1.5%	1.5%
Barbiturates	0.20%	0.20%	0.18%	0.17%	0.15%
Benzodiazepines	0.43%	0.39%	0.36%	0.35%	0.34%
Cocaine	0.27%	0.22%	0.21%	0.22%	0.24%
Marijuana	3.1%	3.6%	3.9%	4.3%	4.5%
MDMA (MDMA/MDA)	0.008%	0.010%	0.005%	0.004%	0.005%
Methadone	0.16%	0.14%	0.13%	0.12%	0.12%
Opiates	0.25%	0.21%	0.17%	0.16%	0.14%
Opiates (Hydrocodone/Hydromorphone)	0.37%	0.33%	0.32%	0.32%	0.29%
Oxycodones (Oxycodone/Oxymorphone)	0.34%	0.29%	0.29%	0.28%	0.27%
PCP	0.011%	0.009%	0.008%	0.008%	0.007%
Propoxyphene	0.000%	0.001%	0.000%	0.000%	0.000%

**Table 6a. Positivity Rates by Drug Category – Urine Drug Tests  
(For General U.S. Workforce Pre-employment only, as a percentage of all such tests)**

*(Nearly 60,000 tests from January to December 2023)*

<b>Drug Category</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Fentanyl	0.17%	0.14%	0.13%	0.16%

**Table 7. Positivity Rates by Drug Category – Urine Drug Tests  
(For Combined U.S. Workforce, as a percentage of all such tests)**

*(More than 8.4 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM	0.015%	0.011%	0.008%	0.004%	0.004%
Amphetamines (Amphetamine/Methamphetamine)	1.1%	1.1%	1.1%	1.2%	1.3%
Barbiturates	0.20%	0.20%	0.18%	0.17%	0.15%
Benzodiazepines	0.43%	0.39%	0.36%	0.35%	0.34%
Cocaine	0.26%	0.21%	0.21%	0.22%	0.23%
Marijuana	2.5%	2.7%	2.9%	3.1%	3.1%
MDMA (MDMA/MDA)	0.005%	0.006%	0.004%	0.003%	0.004%
Methadone	0.16%	0.14%	0.13%	0.12%	0.12%
Opiates	0.22%	0.17%	0.15%	0.14%	0.12%
Opiates (Hydrocodone/Hydromorphone)	0.35%	0.31%	0.28%	0.26%	0.24%
Oxycodones (Oxycodone/Oxymorphone)	0.30%	0.24%	0.24%	0.23%	0.21%
PCP	0.011%	0.010%	0.008%	0.008%	0.007%
Propoxyphene	0.000%	0.001%	0.000%	0.000%	0.000%

**Table 8. Non-Negative Rates by Specimen Validity Test (SVT)<sup>2</sup> Category – Urine Drug Tests  
(For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)**

*(More than 2.8 million tests from January to December 2023)*

<b>SVT Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Acid-Base	0.010%	0.009%	0.009%	0.008%	0.008%
Invalid	0.21%	0.20%	0.26%	0.30%	0.41%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.017%	0.016%	0.014%	0.017%	0.08%

<sup>2</sup>Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

**Table 9. Non-Negative Rates by Specimen Validity Test (SVT) Category – Urine Drug Tests  
(For General U.S. Workforce, as a percentage of all such tests)**

*(More than 5.5 million tests from January to December 2023)*

<b>SVT Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Acid-Base	0.009%	0.009%	0.009%	0.009%	0.008%
Invalid	0.18%	0.17%	0.26%	0.31%	0.45%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.015%	0.012%	0.013%	0.015%	0.11%

**Table 10. Non-Negative Rates by Drug/SVT Category – Urine Drug Tests  
(For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all non-negatives)**

*(More than 80 thousand non-negative test results from January to December 2023)*

<b>Drug/SVT Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM	0.40%	0.31%	0.18%	0.11%	0.11%
Acid-Base	0.34%	0.35%	0.33%	0.29%	0.29%
Amphetamines (Amphetamine/Methamphetamine)	24.3%	25.9%	26.6%	26.8%	26.2%
Cocaine	9.1%	8.1%	8.0%	7.6%	7.2%
Invalid	7.5%	7.9%	10.0%	10.9%	14.1%
Marijuana	31.5%	31.9%	33.1%	35.2%	32.9%
MDMA (MDMA/MDA)	0.09%	0.09%	0.08%	0.09%	0.10%
Opiates (Codeine/Morphine)	4.2%	3.9%	3.1%	3.0%	2.4%
Opiates (Hydrocodone/Hydromorphone)	12.3%	12.0%	10.2%	8.6%	7.6%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	9.3%	8.5%	7.5%	6.5%	6.0%
PCP	0.41%	0.43%	0.38%	0.33%	0.29%
Substituted	0.61%	0.65%	0.56%	0.60%	2.7%

**Table 11. Non-Negative Rates by Drug/SVT Category – Urine Drug Tests  
(For General U.S. Workforce, as a percentage of all non-negatives)**

*(More than 350 thousand non-negative test results from January to December 2023)*

<b>Drug/SVT Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM	0.09%	0.08%	0.06%	0.03%	0.03%
Acid-Base	0.16%	0.15%	0.15%	0.14%	0.13%
Amphetamines (Amphetamine/Methamphetamine)	22.7%	21.5%	22.1%	23.6%	23.9%
Barbiturates	2.2%	2.0%	1.9%	1.6%	1.4%
Benzodiazepines	4.6%	3.9%	3.7%	3.4%	3.1%
Cocaine	4.7%	3.7%	3.4%	3.6%	3.7%
Invalid	3.1%	3.0%	4.3%	5.0%	7.0%
Marijuana	53.1%	57.8%	57.5%	56.1%	53.2%
MDMA (MDMA/MDA)	0.05%	0.06%	0.03%	0.03%	0.03%
Methadone	1.7%	1.4%	1.3%	1.1%	1.1%
Opiates	4.5%	3.5%	2.9%	2.6%	2.3%
Opiates (Hydrocodone/Hydromorphone)	0.87%	0.91%	0.85%	0.91%	0.85%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	1.9%	1.6%	1.6%	1.6%	1.5%
PCP	0.20%	0.16%	0.13%	0.12%	0.11%
Propoxyphene	0.005%	0.007%	0.002%	0.003%	0.002%
Substituted	0.26%	0.21%	0.21%	0.24%	1.7%

**Table 12. Non-Negative Rates by Drug/SVT Category – Urine Drug Tests  
(For Combined U.S. Workforce, as a percentage of all non-negatives)**

*(Nearly 430 thousand non-negative test results from January to December 2023)*

<b>Drug/SVT Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM	0.14%	0.12%	0.08%	0.04%	0.04%
Acid-Base	0.19%	0.18%	0.17%	0.17%	0.16%
Amphetamines (Amphetamine/Methamphetamine)	22.9%	22.2%	22.8%	24.2%	24.3%
Barbiturates	1.8%	1.7%	1.6%	1.3%	1.2%
Benzodiazepines	3.9%	3.3%	3.1%	2.8%	2.5%
Cocaine	5.4%	4.4%	4.1%	4.2%	4.4%
Invalid	3.8%	3.8%	5.2%	6.0%	8.4%
Marijuana	49.7%	53.6%	53.7%	52.6%	49.3%
MDMA (MDMA/MDA)	0.06%	0.07%	0.04%	0.04%	0.04%
Methadone	1.4%	1.1%	1.1%	0.93%	0.89%
Opiates	4.4%	3.6%	2.9%	2.6%	2.3%
Opiates (Hydrocodone/Hydromorphone)	2.7%	2.7%	2.3%	2.2%	2.1%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	3.1%	2.7%	2.5%	2.4%	2.4%
PCP	0.23%	0.20%	0.17%	0.16%	0.14%
Propoxyphene	0.004%	0.006%	0.002%	0.003%	0.002%
Substituted	0.31%	0.28%	0.26%	0.30%	1.9%

**Table 13. Positivity Rates by Testing Category – Oral Fluid Drug Tests  
(For General U.S. Workforce)**

*(More than 1.3 million tests from January to December 2023)*

<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
10.5%	13.6%	7.3%	3.2%	3.3%

**Table 14. Positivity Rates by Testing Reason – Oral Fluid Drug Tests  
(For General U.S. Workforce)**

*(More than 1.3 million tests from January to December 2023)*

<b>Testing Reason</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Post-Accident	5.4%	5.8%	8.5%	9.9%	10.9%
Pre-Employment	10.7%	13.9%	7.1%	2.8%	3.0%
Random	6.0%	5.6%	5.5%	4.2%	4.2%

**Table 15. Positivity Rates by Drug Category – Oral Fluid Drug Tests  
(For General U.S. Workforce)**

*(More than 1.3 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Amphetamine	0.67%	0.71%	0.80%	0.74%	0.84%
Cocaine/Metabolite	0.57%	0.58%	0.85%	0.83%	1.1%
Marijuana	9.1%	12.3%	14.8%	10.4%	9.9%
Methamphetamine	0.49%	0.53%	0.67%	0.70%	0.66%
Opiates	0.35%	0.31%	0.27%	0.22%	0.17%
Oxycodones	0.28%	0.24%	0.24%	0.23%	0.20%
PCP	0.05%	0.04%	0.05%	0.04%	0.03%

**Table 16. Positivity Rates by Testing Category – Hair Drug Tests  
(For General U.S. Workforce)**

*(Nearly 73 thousand tests from January to December 2023)*

<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
11.2%	12.8%	13.1%	13.1%	15.5%

**Table 17. Positivity Rates by Testing Reason – Hair Drug Tests  
(For General U.S. Workforce)**

*(Nearly 73 thousand tests from January to December 2023)*

<b>Testing Reason</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment	9.0%	9.8%	10.1%	9.9%	12.5%
Random	12.0%	16.7%	18.3%	19.8%	19.1%



**Table 18a. Positivity Rates by Drug Category – Hair Drug Tests  
(For General U.S. Workforce)**

*(Old Technology)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>
Amphetamines (Methamphetamine)	2.4%	2.6%	2.4%
Cocaine	3.2%	3.2%	2.8%
Marijuana	7.1%	8.7%	9.8%
Opiates	0.32%	0.29%	0.20%
PCP	0.012%	0.03%	0.012%

**Table 18b. Positivity Rates by Drug Category – Hair Drug Tests  
(For General U.S. Workforce)**

*(Nearly 73 thousand tests from January to December 2023 – New Technology)*

<b>Drug Category</b>		<b>2021</b>	<b>2022</b>	<b>2023</b>
6-AM		0.08%	0.05%	0.04%
Amphetamine		1.8%	1.7%	1.6%
Benzoylcegonine		1.1%	1.1%	1.3%
Cocaine		2.7%	2.9%	3.4%
Marijuana		9.5%	10.3%	12.5%
MDA		0.03%	0.02%	0.02%
MDMA		0.13%	0.08%	0.09%
Methamphetamine		2.1%	1.9%	1.8%
Opiates (Codeine/Hydrocodone)		0.37%	0.29%	0.24%
Opiates (Morphine/Hydromorphone)		0.06%	0.04%	0.03%
Oxycodone		0.60%	0.56%	0.45%
Oxymorphone		0.03%	0.05%	0.03%
PCP		0.02%	0.02%	0.02%

**Table 19. Post-Accident vs. Pre-Employment Positivity Rates for Marijuana – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)**

*(More than 2.8 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.90%	0.93%	0.99%	1.0%	1.0%	0.95%	1.1%	1.3%	1.2%
Post-Accident (PA)	1.1%	1.2%	1.3%	1.5%	1.6%	1.6%	1.8%	2.1%	2.2%
% Difference PE vs. PA	22.2%	29.0%	31.3%	50.0%	60.0%	68.4%	63.6%	61.5%	83.3%

**Table 20. Post-Accident vs. Pre-Employment Positivity Rates for Marijuana – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)**

*(More than 5.5 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	2.3%	2.4%	2.6%	2.8%	3.1%	3.7%	4.1%	4.6%	4.8%
Post-Accident (PA)	3.5%	3.8%	4.2%	4.8%	5.7%	6.4%	6.7%	7.3%	7.5%
% Difference PE vs. PA	52.2%	58.3%	61.5%	71.4%	83.9%	73.0%	63.4%	58.7%	56.3%

**Table 21. Post-Accident vs. Pre-Employment Positivity Rates for Cocaine – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)**

*(More than 2.8 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.27%	0.21%	0.21%	0.21%	0.21%
Post-Accident (PA)	0.47%	0.44%	0.46%	0.43%	0.46%
% Difference PE vs. PA	74.1%	109.5%	119.0%	104.8%	119.0%

**Table 22. Post-Accident vs. Pre-Employment Positivity Rates for Cocaine – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)**

*(More than 5.5 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.23%	0.18%	0.18%	0.20%	0.21%
Post-Accident (PA)	0.73%	0.63%	0.66%	0.66%	0.71%
% Difference PE vs. PA	217.4%	250.0%	266.7%	230.0%	238.1%

**Table 23. Post-Accident vs. Pre-Employment Positivity Rates for Opiates (Hydrocodone/Hydromorphone) – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)**

*(More than 2.8 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.27%	0.22%	0.21%	0.18%	0.17%
Post-Accident (PA)	0.89%	0.81%	0.75%	0.68%	0.60%
% Difference PE vs. PA	229.6%	268.2%	257.1%	277.8%	252.9%

**Table 24. Post-Accident vs. Pre-Employment Positivity Rates for Opiates (Hydrocodone/Hydromorphone) – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)**

*(More than 5.5 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.26%	0.23%	0.24%	0.24%	0.20%
Post-Accident (PA)	1.1%	0.95%	1.0%	1.0%	0.91%
% Difference PE vs. PA	323.1%	313.0%	316.7%	316.7%	355.0%

**Table 25. Post-Accident vs. Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) – Urine Drug Tests (For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all such tests)**

*(More than 2.8 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.22%	0.17%	0.17%	0.16%	0.15%
Post-Accident (PA)	0.58%	0.52%	0.50%	0.44%	0.49%
% Difference PE vs. PA	163.6%	205.9%	194.1%	175.0%	226.7%

**Table 26. Post-Accident vs. Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) – Urine Drug Tests (For General U.S. Workforce, as a percentage of all such tests)**

*(More than 5.5 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Pre-Employment (PE)	0.28%	0.24%	0.24%	0.24%	0.23%
Post-Accident (PA)	0.77%	0.62%	0.72%	0.69%	0.65%
% Difference PE vs. PA	175.0%	158.3%	200.0%	187.5%	182.6%

**Table 27. Marijuana Positivity by 2023 State Legalized Use Status – Urine Drug Tests  
(For Federally Mandated, Safety-Sensitive Workforce, as a percentage of all tests for Marijuana Metabolite)**

*(More than 2.8 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Recreational Use	0.74%	0.83%	0.88%	0.93%	0.95%	0.87%	0.93%	1.1%	1.1%
Medical Use Only	0.71%	0.76%	0.82%	0.87%	0.89%	0.78%	0.84%	0.93%	0.88%
Neither Recreational nor Medical Use	0.68%	0.75%	0.82%	0.87%	0.83%	0.72%	0.78%	0.89%	0.83%
National	0.71%	0.78%	0.84%	0.88%	0.88%	0.79%	0.86%	0.98%	0.95%

**Table 28. Marijuana Positivity by 2023 State Legalized Use Status – Urine Drug Tests  
(For General U.S. Workforce, as a percentage of all tests for Marijuana Metabolite)**

*(More than 5.5 million tests from January to December 2023)*

<b>Drug Category</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>
Recreational Use	2.4%	2.5%	2.7%	3.1%	3.6%	4.1%	4.8%	5.5%	5.8%
Medical Use Only	2.0%	2.1%	2.1%	2.4%	2.7%	3.2%	3.6%	4.0%	4.0%
Neither Recreational nor Medical Use	2.7%	2.7%	2.8%	2.7%	2.7%	3.0%	3.0%	3.1%	3.3%
National	2.4%	2.5%	2.6%	2.8%	3.1%	3.6%	3.9%	4.3%	4.5%